LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014

Journal of Travel Medicine

Volumn 21, Issue 2, 2014, Pages 116-129

  Blum, Johannes ^a,b,c   Buffet, Pierre ^d,e   Visser, Leo ^c,f   Harms, Gundel ^g   Bailey, Mark S ^h   Caumes, Eric ^c,e   Clerinx, Jan ^c,i   Van Thiel, Pieter P A M ^j   Morizot, Gloria ^d   Hatz, Christoph ^a,b,c   Dorlo, Thomas P C ^k   Lockwood, Diana N J ^l  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c TropNet European Network for Tropical Medicine and Travel Health   (Switzerland)

^d SORBONNE UNIVERSITÉ   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h QUEEN ELIZABETH HOSPITAL   (United Kingdom)

ⁱ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k UTRECHT UNIVERSITY   (Netherlands)

^l LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; FLUCONAZOLE; KETOCONAZOLE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE;

EMPORIATRICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; MIXED INFECTION; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; REVIEW; SKIN LEISHMANIASIS; SYSTEMIC THERAPY;

ANTIPROTOZOAL AGENTS; DISEASE OUTBREAKS; HUMANS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; PRACTICE GUIDELINES AS TOPIC; TRAVEL; WORLD HEALTH;

EID: 84895788531     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12089     Document Type: Review

References (144)

1. Boecken G, Sunderkotter C, Bogdan C, et al. Diagnosis and therapy of cutaneous and mucocutaneous leishmaniasis in Germany. J Dtsch Dermatol Ges 2011; 9: 1-51.
2. Bailey MS, Lockwood DN,. Cutaneous leishmaniasis. Clin Dermatol 2007; 25: 203-211.
3. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53: 158-166.
4. Schwartz E, Hatz C, Blum J,. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006; 6: 342-349.
5. Blum JA, Hatz CF,. Treatment of cutaneous leishmaniasis in travelers 2009. J Travel Med 2009; 16: 123-131.
6. Mitropoulos P, Konidas P, Durkin-Konidas M,. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol 2010; 63: 309-322.
7. Goto H, Lindoso JA,. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8: 419-433.
8. Buffet PA, Rosenthal E, Gangneux JP, et al. Therapy of leishmaniasis in France: consensus on proposed guidelines. Presse Med 2011; 40: 173-184.
9. Control of the Leishmaniases Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Control of the Leishmaniases 2010; 949.
10. Blum J,. LeishMan: harmonising diagnostic and clinical management of leishmaniasis in Europe. Euro Surveill 2013; 18: 62.
11. Schubach A, Haddad F, Oliveira-Neto MP, et al. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J Infect Dis 1998; 178: 911-914.
12. Mendonca MG, de Brito MEF, Rodrigues EHG, et al. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189: 1018-1023.
13. Blum J, Lockwood DNJ, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health 2012; 4: 153-163.
14. Armijos RX, Weigel MM, Calvopina M, et al. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 2004; 91: 153-160.
15. Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66: 147-151.
16. Krause G, Kroeger A,. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 1994; 88: 92-94.
17. Oliveira-Neto MP, Schubach A, Mattos M, et al. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil-an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997; 36: 463-468.
18. Arana BA, Mendoza CE, Rizzo NR, et al. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001; 65: 466-470.
19. Herwaldt BL, Berman JD,. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296-306.
20. Antezana G, Zeballos R, Mendoza C, et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992; 86: 31-33.
21. Wise ES, Armstrong MS, Watson J, Lockwood DN,. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with new world cutaneous leishmaniasi. PLoS Negl Trop Dis 2012; 6: e1688.
22. Ribeiro AL, Drummond JB, Volpini AC, et al. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 1999; 32: 297-301.
23. Lawn SD, Armstrong M, Chilton D, et al. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100: 264-269.
24. Hepburn NC, Siddique I, Howie AF, et al. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet 1993; 342: 238-239.
25. Hepburn NC,. Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87: 691.
26. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998; 27: 1457-1464.
27. Gasser RA Jr, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18: 83-90.
28. Rodrigues ML, Costa RS, Souza CS, et al. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 1999; 41: 33-37.
29. Brummitt CF, Porter JA, Herwaldt BL,. Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Clin Infect Dis 1996; 22: 878-879.
30. Wortmann GW, Aronson NE, Byrd JC, et al. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis 1998; 27: 509-512.
31. Jeddi F, Caumes E, Thellier M, et al. Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg 2009; 80: 939-940.
32. Hellier I, Dereure O, Tournillac I, et al. Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 2000; 200: 120-123.
33. Lightburn E, Morand JJ, Meynard JB, et al. Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate. Med Trop (Mars) 2003; 63: 35-44.
34. Delobel P, Pradinaud R,. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J Antimicrob Chemother 2003; 51: 1319-1320.
35. Soto-Mancipe J, Grogl M, Berman JD,. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16: 417-425.
36. Nacher M, Carme B, Sainte MD, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001; 95: 331-336.
37. Soto J, Berman J,. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006; 100 (Suppl 1): S34-S40.
38. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 (Suppl 1): S26-S33.
39. Saenz RE, Paz H, Berman JD,. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89: 147-155.
40. Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52: 2855-2860.
41. Dorlo TPC, Balasegaram M, Lima MA, et al. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012; 67: 1996-2004.
42. Asilian A, Sadeghinia A, Faghihi G, et al. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43: 281-283.
43. Faris RM, Jarallah JS, Khoja TA, et al. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993; 32: 610-612.
44. Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996; 35: 594-597.
45. Eldarouti MA, Alrubaie SM,. Cutaneous leishmaniasis-treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990; 29: 56-59.
46. Salmanpour R, Razmavar MR, Abtahi N,. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 1115-1116.
47. el On J, Halevy S, Grunwald MH, et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27: 227-231.
48. Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3: e432.
49. el On J, Livshin R, Paz ZE, et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1985; 291: 1280-1281.
50. Asilian A, Jalayer T, Nilforooshzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003; 81: 353-359.
51. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368: 524-532.
52. Bumb RA, Prasad N, Khandelwal K, et al. Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol 2013; 168: 1114-1119.
53. Safi N, Davis GD, Nadir M, et al. Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial. Mil Med 2012; 177: 345-351.
54. Sadeghian G, Nilfroushzadeh MA, Iraji F,. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007; 32: 371-374.
55. Aronson NE, Wortmann GW, Byrne WR, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 2010; 4: e628.
56. van Thiel PP, Leenstra T, Kager PA, et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 2010; 50: 80-83.
57. Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007; 103: 33-40.
58. Rahman SB, ul Bari A, Mumtaz N,. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak 2007; 17: 132-135.
59. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-895.
60. Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007; 76: 48-52.
61. Emad M, Hayati F, Fallahzadeh MK, et al. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 2011; 64: 606-608.
62. Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83: 1028-1033.
63. Sadeghian G, Nilforoushzadeh MA,. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 819-821.
64. Momeni AZ, Reiszadae MR, Aminjavaheri M,. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 2002; 41: 441-443.
65. Firdous R, Yasinzai M, Ranja K,. Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis. Int J Dermatol 2009; 48: 758-762.
66. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005; 19: 80-83.
67. Morizot G, Kendjo E, Mouri O, et al. Travelers with cutaneous leishmaniasis cured without systemic therapy. Clin Infect Dis 2013; 57: 370-380.
68. Bryceson AD, Murphy A, Moody AH,. Treatment of "Old World" cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994; 88: 226-228.
69. Khatami A, Firooz A, Gorouhi F, et al. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57: 335-29.
70. Belazzoug S, Neal RA,. Failure of meglumine antimoniate to cure cutaneous lesions due to leishmania-major in Algeria. Trans R Soc Trop Med Hyg 1986; 80: 670-671.
71. Weinrauch L, Livshin R, Even-Paz Z, et al. Efficacy of ketoconazole in cutaneous leishmaniasis. Arch Dermatol Res 1983; 275: 353-354.
72. Salmanpour R, Handjani F, Nouhpisheh MK,. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatol Treat 2001; 12: 159-162.
73. Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005; 40: 1148-1155.
74. Solomon M, Pavlotsky F, Leshem E, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25: 973-977.
75. Neub A, Krahl D, Stich A, et al. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges 2008; 6: 1061-1064.
76. Tappe D, Muller A, Stich A,. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment. Am J Trop Med Hyg 2010; 82: 1-3.
77. Killingley B, Lamb LE, Davidson RN,. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol 2009; 103: 171-175.
78. Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006; 142: 1575-1579.
79. Munir A, Janjua SA, Hussain I,. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol Croat 2008; 16: 60-64.
80. Zerehsaz F, Salmanpour R, Handjani F, et al. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol 1999; 38: 610-612.
81. Negera E, Gadisa E, Hussein J, et al. Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. Trans R Soc Trop Med Hyg 2012; 106: 496-503.
82. Junaid AJ,. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol 1986; 25: 470-472.
83. Faber WR, Wonders J, Jensema AJ, et al. Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani. Clin Exp Dermatol 2009; 34: E196-E198.
84. Poeppl W, Walochnik J, Pustelnik T, et al. Short report: cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine. Am J Trop Med Hyg 2011; 84: 562-565.
85. Neumayr ALC, Walter C, Stoeckle M, et al. Successful treatment of imported mucosal leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment. J Travel Med 2012; 19: 124-126.
86. Stoeckle M, Holbro A, Arnold A, et al. Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome. Acta Trop 2013; 128: 168-170.
87. Esfandiarpour I, Alavi A,. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41: 521-524.
88. Boecken G, Weitzel T, Sunderkotter C, et al. Diagnosis and therapy of cutaneous and musculocutaneous Leishmaniasis in Germany. J Dtsch Dermatol Ges 2009; 7 (Suppl 7): s1-s38.
89. Zanger P, Kotter I, Raible A, et al. Case report: successful treatment of cutaneous leishmaniasis caused by leishmania aethiopica with liposomal Amphothericin B in an immunocompromised traveler returning from eritrea. Am J Trop Med Hyg 2011; 84: 692-694.
90. Lopez L, Robayo M, Vargas M, Vélez ID,. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13: 58.
91. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: E57-E61.
92. Rubiano LC, Miranda MC, Arenas SM, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205: 684-692.
93. Soto J, Arana A, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266-1272.
94. Velez I, Lopez L, Sanchez X, et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83: 351-356.
95. Soto J, Buffet P, Grogl M, et al. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50: 107-111.
96. Ballou WR, McClain JB, Gordon DM, et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987; 2: 13-16.
97. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002; 35: 261-267.
98. Lai AFE, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002; 41: 796-800.
99. Neves LO, Talhari AC, Gadelha EPN, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011; 86: 1092-1101.
100. Roussel M, Nacher M, Fremont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2006; 100: 307-314.
101. Chrusciak-Talhari A, Dietze R, Chrusciak TC, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84: 255-260.
102. van der Meide WF, Sabajo LOA, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol 2009; 48: 52-58.
103. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005; 72: 133-137.
104. Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165: 528-534.
105. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78: 210-211.
106. Solomon M, Pavlotzky F, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2013; 68: 284-289.
107. Machado PR, Ampuero J, Guimaraes LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4: e912.
108. Weinrauch L, Cawich F, Craig P, et al. Topical treatment of New World cutaneous leishmaniasis in Belize: a clinical study. J Am Acad Dermatol 1993; 29: 443-446.
109. Soto J, Fuya P, Herrera R, et al. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26: 56-58.
110. Marsden PD,. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80: 859-876.
111. Jones TC, Johnson WD Jr, Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156: 73-83.
112. Herwaldt BL,. Leishmaniasis. Lancet 1999; 354: 1191-1199.
113. Romero GA, Guerra MV, Paes MG, et al. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65: 456-465.
114. Almeida R, D'Oliveira A Jr, Machado P, et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. J Infect Dis 1999; 180: 1735-1737.
115. Seaton RA, Morrison J, Man I, et al. Out-patient parenteral antimicrobial therapy-a viable option for the management of cutaneous leishmaniasis. Q J Med 1999; 92: 659-667.
116. Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007; 195: 1846-1851.
117. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46: 223-231.
118. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007; 56: 612-616.
119. Harms G, Scherbaum H, Reiter-Owona I, et al. Treatment of imported New World cutaneous leishmaniasis in Germany. Int J Dermatol 2011; 50: 1336-1342.
120. Sousa AQ, Frutuoso MS, Moraes EA, et al. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53: 693-695.
121. van Thiel PPAM, van Gool T, Kager PA, et al. Case report: first cases of cutaneous leishmaniasis caused by leishmania (Viannia) naiffi infection in Surinam. Am J Trop Med Hyg 2010; 82: 588-590.
122. van der Snoek EM, Lammers AM, Kortbeek LM, et al. Spontaneous cure of American cutaneous leishmaniasis due to Leishmania naiffi in two Dutch infantry soldiers. Clin Exp Dermatol 2009; 34: E889-E891.
123. Richter J, Hanus I, Haussinger D, et al. Mucosal Leishmania infantum infection. Parasitol Res 2011; 109: 959-962.
124. Faucher B, Pomares C, Fourcade S, et al. Mucosal Leishmania infantum leishmaniasis: specific pattern in a multicentre survey and historical cases. J Infect 2011; 63: 76-82.
125. Kharfi M, Fazaa B, Chaker E, et al. Mucosal localization of leishmaniasis in Tunisia: 5 cases. Ann Dermatol Venereol 2003; 130: 27-30.
126. Amato VS, Tuon FF, Imamura R, et al. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009; 23: 1026-1034.
127. Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis-current scenario and prospects for treatment. Acta Trop 2008; 105: 1-9.
128. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44: 788-793.
129. Bafica A, Oliveira F, Freitas LA, et al. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 2003; 42: 203-207.
130. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001; 65: 87-89.
131. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44: 350-356.
132. Soto J, Rea J, Valderrama M, et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009; 81: 387-389.
133. Franke ED, Llanos-Cuentas A, Echevarria J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994; 51: 77-82.
134. Amato VS, Tuon FF, Camargo RA, et al. Short report: can we use a lower dose of liposomal amphotericin b for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011; 85: 818-819.
135. Aliaga L, Cobo F, Mediavilla JD, et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) 2003; 82: 147-158.
136. Garcia de Marcos JA, Dean FA, Alamillos GF, et al. Localized Leishmaniasis of the oral mucosa. A report of three cases. Med Oral Patol Oral Cir Bucal 2007; 12: E281-E286.
137. Walton BC, Valverde L,. Racial differences in Espundia. Ann Trop Med Parasitol 1979; 73: 23-29.
138. Dorlo TPC, Huitema ADR, Beijnen JH, et al. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 2012; 56: 3864-3872.
139. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis 2007; 45: 478-482.
140. Zanger P, Kotter I, Kremsner P, et al. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Trop Med Int Health 2011; 16: 172.
141. Neumayr A, Buffet P, Visser L, et al. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-alpha antagonists. TMAID 2013; Epub ahead of print.
142. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334.
143. Mosimann V, Neumayr A, Hatz C, et al. Cutaneous Leishmaniasis in Switzerland-first experience with species specific treatment. Infection 2013; Epub ahead of print.
144. Buffet P, Deray G, Grogl M, et al. Tolerance and pharmacokinetics of antimony in a patient with renal-failure. Nephrol Dial Transplant 1995; 10: 1477.